Recruiting NA INTERVENTIONAL 1-arm NCT06258642

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Study of Irinotecan Liposome Combined With Anlotinib as Second-line Regimen in Patients With Small Cell Lung Cancer

Sponsor: Fudan University

Conditions Small Cell Lung Cancer Recurrent

Interventions Anlotinib Irinotecan Liposome

Updated 4 times since 2024 Last updated: Aug 14, 2025 Started: Apr 17, 2024 Primary completion: Apr 30, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Small Cell Lung Cancer Recurrent and is currently actively recruiting participants. Fudan University leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Sep 2025 [monthly]

Not Yet Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting NA
Mar 2024 — Jul 2024 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China